Medicis Pharmaceutical

Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer

Retrieved on: 
Wednesday, November 2, 2022
Dermatology, RNA transfection, Growth, Administration, Acquisition, Tissue, House of Medici, Board, Ophthalmology, Gene expression, Disease, ERA, Epigenome, Osteoarthritis, Ageing, CFO, Therapy, Initial public offering, Conditional sentence, Audit committee, Medicis Pharmaceutical, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has appointed Richard "Ric" Peterson as chief financial officer.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire/ --Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has appointed Richard "Ric" Peterson as chief financial officer.
  • Mr. Peterson, who has served as CFO of numerous public and private biotech and pharmaceutical companies, has deep experience with private financing, public offerings, and complex global transactions.
  • He will oversee all financial functions and fundraising efforts as Turn Bio prepares to launch its clinical programs.
  • During his 25 years of serving as a chief financial officer, Peterson has led traditional fundraising efforts for pre-clinical, clinical and commercial companies, managed initial public offerings and overseen corporate purchases and sales.

Turn Biotechnologies Names 25-year Biotech Industry Veteran Richard Peterson Chief Financial Officer

Retrieved on: 
Wednesday, November 2, 2022
Dermatology, RNA transfection, Growth, Administration, Acquisition, Tissue, House of Medici, Board, Ophthalmology, Gene expression, Disease, ERA, Epigenome, Osteoarthritis, Ageing, CFO, Therapy, Initial public offering, Conditional sentence, Audit committee, Medicis Pharmaceutical, Pharmaceutical industry

MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has appointed Richard "Ric" Peterson as chief financial officer.

Key Points: 
  • MOUNTAIN VIEW, Calif., Nov. 2, 2022 /PRNewswire/ --Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced it has appointed Richard "Ric" Peterson as chief financial officer.
  • Mr. Peterson, who has served as CFO of numerous public and private biotech and pharmaceutical companies, has deep experience with private financing, public offerings, and complex global transactions.
  • He will oversee all financial functions and fundraising efforts as Turn Bio prepares to launch its clinical programs.
  • During his 25 years of serving as a chief financial officer, Peterson has led traditional fundraising efforts for pre-clinical, clinical and commercial companies, managed initial public offerings and overseen corporate purchases and sales.

Biofrontera Inc. Appoints Kevin D. Weber to its Board of Directors

Retrieved on: 
Monday, March 7, 2022
Private Securities Litigation Reform Act, Dermatology, Board, Adoption, PDT, Impetigo, American Academy, DUSA Pharmaceuticals, Board of directors, Medicis Pharmaceutical, Assertio Therapeutics, Therapy, Metabolism, SEC, Company, Advertising, COVID-19, BFRI, Marketing, CEO, Business administration, Pain management, Skin, Nasdaq, GLOBE, Management, Pharmaceutical industry, Paraffin, Western Michigan University

WOBURN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the Company), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Kevin D. Weber to its Board of Directors, expanding Board membership to five Directors.

Key Points: 
  • WOBURN, Mass., March 07, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (the Company), a biopharmaceutical company specializing in the commercialization of dermatological products, announces the appointment of Kevin D. Weber to its Board of Directors, expanding Board membership to five Directors.
  • Mr. Weber is an experienced pharmaceutical executive who brings to Biofrontera more than 30 years of executive and commercialization experience with a particular expertise in product marketing.
  • Prior to Paraffin, Mr. Weber served in senior executive and marketing roles at Depomed, Hyperion Therapeutics and Medicis Pharmaceuticals.
  • From 2016 to 2021 Mr. Weber served as a member of the supervisory board of Biofrontera AG.

Venus Concept Appoints Ross J. Portaro as President of Global Sales

Retrieved on: 
Tuesday, October 12, 2021
Venus, NASDAQ, Company, ARTAS, Beauty, GLOBE, Growth, Industry, Scalp, University, Hair, EMEA, Senior, Medicis Pharmaceutical, FUE, Commerce, Nightclub, Management

TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021.

Key Points: 
  • TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. (Venus Concept or the Company) (NASDAQ: VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021.
  • Mr. Portaro joined Venus Concept as Vice President of EMEA in May, 2021, responsible for developing the sales strategy and managing all sales and utilization activity via direct and distribution sales channels in the region.
  • Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets.
  • Venus Concepts product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Glow, Venus Bliss, Venus Epileve and Venus Viva MD.

Trevi Therapeutics Announces Additions to the Senior Leadership Team

Retrieved on: 
Monday, August 9, 2021
Movement disorders, San Jose State University, Levodopa-induced dyskinesia, Idiopathic pulmonary fibrosis, Acquisition, Growth, Risk, CAO, Marketing, Safety, PN, U.S. Securities and Exchange Commission, TCOE, Medical Affairs Bureau, Private Securities Litigation Reform Act, Hoffmann-La Roche, Fast Track, COVID-19, Anacor, CPA, Parkinson's disease, Business, Golden Gate University, Deloitte, LID, Lehigh University, Medicis Pharmaceutical, Chronic cough, PRISM, Route of administration, CFO, Therapy, Prurigo nodularis, Knowledge, Itch, Certified Public Accountant, Patient, IPF, Connecticut, General Electric, FDA, Marcum, Publication, Nasdaq, Clinical trial, Nalbuphine, DEA, Communication, Cough, Pharmaceutical industry

New CFO and Vice President, Medical Affairs will be instrumental in Trevi's growth as lead trials move towards data

Key Points: 
  • New CFO and Vice President, Medical Affairs will be instrumental in Trevi's growth as lead trials move towards data
    "We are thrilled to welcome Lisa and Danine to our skilled senior leadership team," said Jennifer L. Good, President and Chief Executive Officer of Trevi.
  • Ms. Delfini joins Trevi with 30 years of experience in the financial sector.
  • As a Financial Accounting and Advisory Services Partner at Marcum LLP, Ms. Delfini led a team of professionals who provided advisory services on financial activities to companies.
  • Before joining Trevi, she held varying senior management roles in medical affairs and marketing at companies such as Anacor Pharmaceuticals, Menlo Therapeutics, Medicis Pharmaceutical, Connetics Corporation, VICOM/FCB and Roche Pharmaceuticals.